CP-690550 Treatment Ameliorates Established Disease and Provides Long-Term Therapeutic Effects in an SKG Arthritis Model.
- Author:
Keunhee OH
1
;
Myung Won SEO
;
In Gyu KIM
;
Young Il HWANG
;
Hee Yoon LEE
;
Dong Sup LEE
Author Information
- Publication Type:Original Article
- Keywords: Rheumatoid arthritis; CP-690550; SKG mice; IL-17; IL-10
- MeSH: Arthritis*; Arthritis, Rheumatoid; Cytokines; Humans; Interleukin-10; Interleukin-17; Interleukin-6; Models, Animal; Phosphotransferases; T-Lymphocytes
- From:Immune Network 2013;13(6):257-263
- CountryRepublic of Korea
- Language:English
- Abstract: Although pathogenesis of human rheumatoid arthritis (RA) remains unclear, arthritogenic T cells and downstream signaling mediators have been shown to play critical roles. An increasing numbers of therapeutic options have been added for the effective control of RA. Nevertheless, there is still a category of patients that fails treatment and suffers from progressive disease. The recently developed immunosuppressant CP-690550, a small molecule JAK kinase inhibitor, has been implicated as an important candidate treatment modality for autoimmune arthritis. In this study, we evaluated the therapeutic effect of CP-690550 on established arthritis using an SKG arthritis model, a pathophysiologically relevant animal model for human RA. CP-690550 treatment revealed remarkable long-term suppressive effects on SKG arthritis when administered to the well-advanced disease (clinical score 3.5~4.0). The treatment effect lasted at least 3 more weeks after cessation of drug infusion, and suppression of disease was correlated with the reduced pro-inflammatory cytokines, including IL-17, IFN-gamma, and IL-6 and increased level of immunoregulatory IL-10.
